Pregene Lists on NEEQ, Focused on Cell Therapy Drug Development

Rhino StarReport, July 12 News,Pregene(874090) was listed on the NEEQ today. The company's operating revenues for the year 2021 and the first three quarters of 2022 were RMB 10.6209 million and RMB 66.7506 million, respectively, with net profits attributable to parent company shareholders at -RMB 85.4715 million and RMB 34.5197 million.

Rhino StarThe APP shows that Pregene is an innovative biopharmaceutical company specializing in the research, development, and industrialization of cell therapy drugs. The company has already obtained 1...CAR-T candidate cell drug and 1 TCR-T candidate cell drug IND approval.

Projects under research in the company

As of the date of the public transfer agreement, the company has obtained 32 patents, including 20 invention patents and 12 utility model patents.It is worth noting that in June 2022, the company was recognized by the Shenzhen Municipal Industry and Information Technology Bureau as a specialized, refined, distinctive, and innovative small and medium-sized enterprise.

According to the public transfer book disclosure, the top three sales customers of the company in the first three quarters of 2022 wereGalapagos、Dr. Reddy's Laboratories Ltd、CellPoint B.V.。Sales were 51.8978 million yuan, 9.7313 million yuan, and 3.4853 million yuan, respectively.

In terms of shareholding, the largest shareholder, Shenzhen Pregene Partnership, holds 3.95 million shares, accounting for 39.51% of the company's equity; the SME Development Fund holds 1.24 million shares, accounting for 12.49% of the company's equity.